Document is current
Any future updates will be listed below
-
Authors
Gavish, Avishai
Tyler, Michael https://orcid.org/0000-0003-2128-5247
Greenwald, Alissa C.
Hoefflin, Rouven https://orcid.org/0000-0002-5197-453X
Simkin, Dor
Tschernichovsky, Roi https://orcid.org/0000-0002-3539-1940
Galili Darnell, Noam
Somech, Einav
Barbolin, Chaya
Antman, Tomer
Kovarsky, Daniel
Barrett, Thomas https://orcid.org/0000-0002-6058-1404
Gonzalez Castro, L. Nicolas https://orcid.org/0000-0001-7699-5188
Halder, Debdatta
Chanoch-Myers, Rony
Laffy, Julie
Mints, Michael https://orcid.org/0000-0001-9215-9518
Wider, Adi
Tal, Rotem
Spitzer, Avishay https://orcid.org/0000-0001-6551-9338
Hara, Toshiro
Raitses-Gurevich, Maria
Stossel, Chani
Golan, Talia
Tirosh, Amit
Suvà, Mario L. https://orcid.org/0000-0001-9898-5351
Puram, Sidharth V. https://orcid.org/0000-0003-3543-889X
Tirosh, Itay https://orcid.org/0000-0001-5477-2987
- License Information
-
More Information
Article History
Received: 5 May 2022
Accepted: 25 April 2023
First Online: 31 May 2023
Competing interests
: I.T. is an advisory board member of Immunitas Therapeutics. M.L.S. is an equity holder, scientific co-founder and advisory board member of Immunitas Therapeutics.
